Edgewise Therapeutics Inc. Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.13 (market cap $3.94B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 2.3× Edgewise Therapeutics Inc. Common Stock's market cap, and Edgewise Therapeutics Inc. Common Stock is more actively traded (810,104 versus 779,107). Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| EWTX | KYMR | |
|---|---|---|
Market Cap | $3.94B | $8.87B |
Volume | 810,104 | 779,107 |
Sector | Health | Health |
52-Week High | $48.35 | $127.31 |
52-Week Low | $14.89 | $55.80 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.48B | $8.26B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →